Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Accounts Payables: 2014-2024

Historic Accounts Payables for KalVista Pharmaceuticals (KALV) over the last 6 years, with Dec 2024 value amounting to $5.7 million.

  • KalVista Pharmaceuticals' Accounts Payables was N/A to $5.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.7 million, marking a year-over-year change of. This contributed to the annual value of $9.1 million for FY2024, which is N/A change from last year.
  • KalVista Pharmaceuticals' Accounts Payables amounted to $5.7 million in Q4 2024, which was up 10.16% from $5.2 million recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Accounts Payables registered a high of $10.8 million during Q3 2024, and its lowest value of $641,000 during Q1 2021.
  • For the 2-year period, KalVista Pharmaceuticals' Accounts Payables averaged around $6.3 million, with its median value being $5.2 million (2024).
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Accounts Payables crashed by 78.28% in 2021, and later soared by 113.28% in 2024.
  • KalVista Pharmaceuticals' Accounts Payables (Quarterly) stood at $2.2 million in 2020, then crashed by 78.28% to $641,000 in 2021, then reached $4.9 million in 2023, then grew by 6.17% to $5.7 million in 2024.
  • Its last three reported values are $5.7 million in Q4 2024, $5.2 million for Q4 2024, and $10.8 million during Q3 2024.